Impact of the Conversion of the Immunosuppressive Regimen from Prograf to Advagraf or to Sirolimus in Long-term Stable Liver Transplant Recipients: Indications, Safety, and Outcome

被引:9
|
作者
Perrakis, A. [1 ]
Schwarz, K. [1 ]
Yedibela, S. [1 ]
Croner, R. S. [1 ]
Hohenberger, W. [1 ]
Mueller, V. [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Surg, D-91054 Erlangen, Germany
关键词
MYCOPHENOLATE-MOFETIL MONOTHERAPY; RELEASE TACROLIMUS ADVAGRAF; RENAL-FUNCTION; CALCINEURIN INHIBITOR; THERAPY; HEPATOTOXICITY; TRIAL;
D O I
10.1016/j.transproceed.2011.09.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Compliance problems have arisen due to the twice a day administration of calcineurin inhibitors (CNI). We examined the safety, indications, and efficacy in terms of graft and patient survivals after conversion from tacrolimus to Sirolimus or Advagraf. Patients and Methods. Between January 2006 and December 2009, 36 orthotopic liver transplantation patients underwent conversion of the immunosuppressive regimen from Prograf to either Sirolimus (group 1; n = 10) or Advagraf (group 2; n = 26). A group of patients taking Prograf was used as a control group (group 3; n = 15). We identified 51 patients of mean age 57 years and male:female percentages of 57%:43% from a prospective database. Renal and liver graft functions, patient survival, as well as laboratory and clinical data over at least 12 months (mean, 38) were the investigated parameters. Results. Patients converted to Sirolimus did not show significantly improved renal function at 12 months as evidenced by creatinine levels (1.31 mg/dL +/- 0.47 vs 1.34 mg/dL +/- 0.78) and glomerular filtration rate (GFR, 57 +/- 16 vs 56 +/- 16 mL/min). However, there were significant antiproliferative effects. Patients with a hepatocellular carcinoma in the pretransplantation phase remained without a recurrence. The side effects including ankle edema, aphthae, and tachyarrhythmia absoluta, required reconversion to the CNI. Patients prescribed Advagraf reported a better life quality because of the single administration and a slight, insignificant improvement in renal function. An acute rejection episode was evidenced under either immunosuppresant. Conclusion. Sirolimus is a safe immunosuppressive option in liver transplant recipients suffering from hepatocellular carcinoma. Advagraf showed a lower incidence of side effects than Prograf and probably is not as harmful for renal function, offering better compliance and better life quality.
引用
收藏
页码:3702 / 3707
页数:6
相关论文
共 50 条
  • [1] Impact of the Conversion of the Immunsuppressive Regimen from Prograf to Advagraf or to Sirolimus in Long Term Stable Liver Transplant Recipients. Indications, Safety and Outcome. A Single Center Experience
    Perrakis, Aristotelis
    Schwarz, Kerstin
    Croner, Roland
    Schellerer, Vera
    Lohmueller, Clemens
    Mueller, Volker
    [J]. LIVER TRANSPLANTATION, 2012, 18 : S249 - S249
  • [2] Long-Term Safety of Sirolimus in Liver Transplant Recipients
    Siddiqui, Mohammad
    Ashraf, Taha
    Khorfan, Kamal
    Latack, Katie
    Moonka, Dilip
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S513 - S514
  • [3] LONG-TERM SAFETY OF SIROLIMUS IN LIVER TRANSPLANT RECIPIENTS
    Ashraf, Taha
    Siddiqui, Mohammad B.
    Khorfan, Kamal
    Moonka, Dilip
    [J]. HEPATOLOGY, 2020, 72 : 823A - 824A
  • [4] CONVERSION FROM TWICE-DAILY PROGRAF TO ONCE-DAILY ADVAGRAF IS STRAIGHTFORWARD IN STABLE LIVER TRANSPLANT RECIPIENTS
    Thorburn, D.
    Paczek, L.
    Wolf, P.
    Boillot, O.
    [J]. TRANSPLANT INTERNATIONAL, 2009, 22 : 211 - 211
  • [5] Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients
    Ott, R
    Bussenius-Kammerer, M
    Reck, T
    Koch, CA
    Kissler, H
    Hohenberger, W
    Müller, V
    [J]. TRANSPLANT INTERNATIONAL, 2004, 17 (01) : 39 - 43
  • [6] Clinical Impact of Conversion from Prograf to Advagraf in Simultaneous Kidney-Pancreas Transplant Recipients
    Falconer, S. J.
    Oniscu, G. C.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 774 - 774
  • [7] Significant Lower Trough Level after Conversion from Prograf to Advagraf in Stable Kidney Transplant Recipients
    Wu, M. -J.
    Cheng, C. -Y.
    Shu, K. -H.
    Chen, C. -H.
    Cheng, C. -H.
    Yu, D. -M.
    Chuang, Y. -W.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 355 - 355
  • [8] Long-term Outcome of Conversion to Sirolimus Monotherapy After Liver Transplant
    Uhlmann, Dirk
    Weber, Tonja
    Ludwig, Stefan
    Ludwig, Barbara
    Bartels, Michael
    Hauss, Johann
    Jonas, Sven
    Witzigmann, Helmut
    [J]. EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2012, 10 (01) : 30 - 38
  • [10] The Impact of Conversion from Prograf to Generic Tacrolimus in Liver Transplant Recipients With Stable Graft Function
    Del Gaudio, Massimo
    Cescon, Matteo
    Bertuzzo, Valentina
    Amaduzzi, Annalisa
    Ravaioli, Matteo
    Cucchetti, Alessandro
    Pinna, Antonio Daniele
    [J]. TRANSPLANTATION, 2017, 101 (05) : S11 - S11